| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8232030 | International Journal of Radiation Oncology*Biology*Physics | 2010 | 6 Pages |
Abstract
Vandetanib can be safely combined with RT and TMZ in GBM patients. A Phase II study in which patients are randomized to vandetanib 100 mg daily with RT and TMZ or RT and TMZ alone is underway.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Jan M.D., Andrew D. M.D., Eric T. M.D., Lisa M. MSN., Debra C. RN, OCN., Abigail MSN., Santosh M.D., Ph.D., Christine BA., Mary BA., Phuong BS., David M.D., Tracy T. M.D., M.P.H., Keith L. M.D., Ph.D., Geoffrey M.D., Alona M.A., Stephanie E. M.D.,